|
rs1042838
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Patients carrying rs1042838 G/T, rs590688 C/C, and rs10895068 G/A genotypes had higher risk of breast cancer, while carriage of rs3740753 G/G genotype was associated with marginal reduction in breast cancer risk.
|
29302853 |
2020 |
|
rs1042838
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Patients carrying rs1042838 G/T, rs590688 C/C, and rs10895068 G/A genotypes had higher risk of breast cancer, while carriage of rs3740753 G/G genotype was associated with marginal reduction in breast cancer risk.
|
29302853 |
2020 |
|
rs1042838
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
rs1042838
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
rs1042838
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
We conclude that the leucine allele of the V660L SNP may be associated with a small increase in breast cancer risk, while the other four PGR SNPs, +44C/T (rs518162), +331G/A (rs10895068), H770H (rs1042839) and Q886Q (rs500760), do not substantially increase breast cancer risk.
|
17592773 |
2008 |
|
rs1042838
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
We conclude that the leucine allele of the V660L SNP may be associated with a small increase in breast cancer risk, while the other four PGR SNPs, +44C/T (rs518162), +331G/A (rs10895068), H770H (rs1042839) and Q886Q (rs500760), do not substantially increase breast cancer risk.
|
17592773 |
2008 |
|
rs1042838
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
After both stages, only one SNP was significantly associated with an increased risk of breast cancer - the PGR-12 (rs1042638) V660L valine to leucine polymorphism [VL heterozygotes (odds ratio, 1.13; 95% confidence interval, 1.03-1.24) and the LL homozygotes (odds ratio, 1.30; 95% confidence interval, 0.98-1.73), P(het) = 0.008, P(trend) = 0.002].
|
16614108 |
2006 |
|
rs1042838
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
After both stages, only one SNP was significantly associated with an increased risk of breast cancer - the PGR-12 (rs1042638) V660L valine to leucine polymorphism [VL heterozygotes (odds ratio, 1.13; 95% confidence interval, 1.03-1.24) and the LL homozygotes (odds ratio, 1.30; 95% confidence interval, 0.98-1.73), P(het) = 0.008, P(trend) = 0.002].
|
16614108 |
2006 |
|
rs1042838
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
Overall, our study does not support an association between the Val660-->Leu PROGINS polymorphism and breast cancer risk.
|
15535845 |
2004 |
|
rs1042838
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Overall, our study does not support an association between the Val660-->Leu PROGINS polymorphism and breast cancer risk.
|
15535845 |
2004 |
|
rs1042838
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
|
12010857 |
2002 |
|
rs1042838
|
|
Malignant neoplasm of breast
|
|
0.060 |
GeneticVariation
|
BEFREE |
The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
|
12010857 |
2002 |
|
rs10895068
|
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, carriage of rs10895068</span> minor allele in breast cancer women were also associated with age at first pregnancy, hormone receptor (RH) status, and previous use of oral contraceptives.
|
29302853 |
2020 |
|
rs10895068
|
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, carriage of rs10895068</span> minor allele in breast cancer women were also associated with age at first pregnancy, hormone receptor (RH) status, and previous use of oral contraceptives.
|
29302853 |
2020 |
|
rs10895068
|
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Many published studies have estimated the association between the +331G/A (rs10895068) polymorphism in the progesterone receptor (PgR) gene and breast cancer risk.
|
29084518 |
2017 |
|
rs10895068
|
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Many published studies have estimated the association between the +331G/A (rs10895068) polymorphism in the progesterone receptor (PgR) gene and breast cancer risk.
|
29084518 |
2017 |
|
rs10895068
|
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
To date, many studies have evaluated the association between a functional polymorphism in the PgR gene promoter (+331G>A, rs10895068) and breast cancer risk; however, the result is still ambiguous and inconclusive.
|
20076999 |
2010 |
|
rs10895068
|
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
To date, many studies have evaluated the association between a functional polymorphism in the PgR gene promoter (+331G>A, rs10895068) and breast cancer risk; however, the result is still ambiguous and inconclusive.
|
20076999 |
2010 |
|
rs10895068
|
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
We conclude that the leucine allele of the V660L SNP may be associated with a small increase in breast cancer risk, while the other four PGR SNPs, +44C/T (rs518162), +331G/A (rs10895068), H770H (rs1042839) and Q886Q (rs500760), do not substantially increase breast cancer risk.
|
17592773 |
2008 |
|
rs10895068
|
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
We conclude that the leucine allele of the V660L SNP may be associated with a small increase in breast cancer risk, while the other four PGR SNPs, +44C/T (rs518162), +331G/A (rs10895068), H770H (rs1042839) and Q886Q (rs500760), do not substantially increase breast cancer risk.
|
17592773 |
2008 |
|
rs1042838
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that the two polymorphisms of PGR, Alu insertion and Val660Leu, may contribute to ovarian cancer susceptibility as low-penetrance risk factors.
|
25228088 |
2015 |
|
rs1042838
|
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that the two polymorphisms of PGR, Alu insertion and Val660Leu, may contribute to ovarian cancer susceptibility as low-penetrance risk factors.
|
25228088 |
2015 |
|
rs1042838
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that the two polymorphisms of PGR, Alu insertion and Val660Leu, may contribute to ovarian cancer susceptibility as low-penetrance risk factors.
|
25228088 |
2015 |
|
rs1042838
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V</span>660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92).
|
15718480 |
2005 |
|
rs1042838
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V</span>660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92).
|
15718480 |
2005 |